Oncopeptides presented survival data from the phase II-study O-12-M1 of Ygalo® (melflufen) at the 59th Annual Meeting of ASH today
(WorldNews Sweden)

Stockholm - December 10th, 2017 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that the first survival data were presented at the annual meeting of the American Society of Hematology from the phase II-study O-12-M1 in late-stage patients with Relapsed Refractory Multiple Myeloma (RRMM). Summary of key results presentedThe results show a median progression-free survival (PFS) of 5.7 months, a median overall survival (OS) of 20.7 months and an overall response rate of 31%. The data are very encouraging and compares favorably with other clinical studies in this patient population. CEO comments on O-12-M1`Myeloma patients that primarily are treated with lenalidomide and proteasome...